Literature DB >> 23138961

Randomized controlled trial of contingency management for stimulant use in community mental health patients with serious mental illness.

Michael G McDonell1, Debra Srebnik, Frank Angelo, Sterling McPherson, Jessica M Lowe, Andrea Sugar, Robert A Short, John M Roll, Richard K Ries.   

Abstract

OBJECTIVE: The primary objective of this study was to determine whether contingency management was associated with increased abstinence from stimulant drug use in stimulant-dependent patients with serious mental illness treated in a community mental health center. Secondary objectives were to determine whether contingency management was associated with reductions in use of other substances, psychiatric symptoms, HIV risk behavior, and inpatient service utilization.
METHOD: A randomized controlled design was used to compare outcomes of 176 outpatients with serious mental illness and stimulant dependence. Participants were randomly assigned to receive 3 months of contingency management for stimulant abstinence plus treatment as usual or treatment as usual with reinforcement for study participation only. Urine drug tests and self report, clinician-report, and service utilization outcomes were assessed during the 3-month treatment period and the 3-month follow-up period.
RESULTS: Although participants in the contingency management condition were significantly less likely to complete the treatment period than those assigned to the control condition (42% compared with 65%), they were 2.4 times (95% CI=1.9–3.0)more likely to submit a stimulant-negative urine test during treatment. Compared with participants in the control condition,they had significantly lower levels of alcohol use, injection drug use, and psychiatric symptoms and were one-fifth as likely as those assigned to the control condition to be admitted for psychiatric hospitalization during treatment. They also reported significantly fewer days of stimulant drug use during the 3-month follow-up.
CONCLUSIONS: When added to treatment as usual, contingency management is associated with large reductions in stimulant,injection drug, and alcohol use.Reductions in psychiatric symptoms and hospitalizations are important secondary benefits.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23138961      PMCID: PMC4242089          DOI: 10.1176/appi.ajp.2012.11121831

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  39 in total

1.  Treating substance abuse in schizophrenia. An initial report.

Authors:  M E Bennett; A S Bellack; J S Gearon
Journal:  J Subst Abuse Treat       Date:  2001-03

2.  Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study.

Authors:  D A Regier; M E Farmer; D S Rae; B Z Locke; S J Keith; L L Judd; F K Goodwin
Journal:  JAMA       Date:  1990-11-21       Impact factor: 56.272

3.  Co-occurring disorders among mentally ill jail detainees. Implications for public policy.

Authors:  K M Abram; L A Teplin
Journal:  Am Psychol       Date:  1991-10

4.  Homelessness and mental illness in a professional- and peer-led cocaine treatment clinic.

Authors:  M Galanter; H Dermatis; S Egelko; G De Leon
Journal:  Psychiatr Serv       Date:  1998-04       Impact factor: 3.084

5.  Cognitive-behavioural therapy for substance use disorders in people with psychotic disorders: Randomised controlled trial.

Authors:  Amanda Baker; Sandra Bucci; Terry J Lewin; Frances Kay-Lambkin; Paul M Constable; Vaughan J Carr
Journal:  Br J Psychiatry       Date:  2006-05       Impact factor: 9.319

Review 6.  A systematic review of psychosocial research on psychosocial interventions for people with co-occurring severe mental and substance use disorders.

Authors:  Robert E Drake; Erica L O'Neal; Michael A Wallach
Journal:  J Subst Abuse Treat       Date:  2007-06-15

7.  A randomized clinical trial of a new behavioral treatment for drug abuse in people with severe and persistent mental illness.

Authors:  Alan S Bellack; Melanie E Bennett; Jean S Gearon; Clayton H Brown; Ye Yang
Journal:  Arch Gen Psychiatry       Date:  2006-04

8.  Outcomes of managing disability benefits among patients with substance dependence and severe mental illness.

Authors:  Richard K Ries; Dennis G Dyck; Robert Short; Debra Srebnik; Anastasia Fisher; Katherine A Comtois
Journal:  Psychiatr Serv       Date:  2004-04       Impact factor: 3.084

9.  Implementation of integrated dual disorders treatment: a qualitative analysis of facilitators and barriers.

Authors:  Mary F Brunette; Dianne Asher; Rob Whitley; Wilma J Lutz; Barbara L Wieder; Amanda M Jones; Gregory J McHugo
Journal:  Psychiatr Serv       Date:  2008-09       Impact factor: 3.084

10.  Identifying barriers to mental health system improvements: an examination of community participation in assertive community treatment programs.

Authors:  Patricia A Wakefield; Glen E Randall; David A Richards
Journal:  Int J Ment Health Syst       Date:  2011-11-07
View more
  55 in total

1.  Contingency Management Reduces Symptoms of Psychological and Emotional Distress among Homeless, Substance-dependent Men Who Have Sex with Men.

Authors:  Jesse B Fletcher; Steven Shoptaw; James A Peck; Cathy J Reback
Journal:  Ment Health Subst Use       Date:  2014-11-01

2.  Contingency management for patients with dual disorders in intensive outpatient treatment for addiction.

Authors:  Thomas M Kelly; Dennis C Daley; Antoine B Douaihy
Journal:  J Dual Diagn       Date:  2014

Review 3.  Contingency management treatment for substance use disorders: How far has it come, and where does it need to go?

Authors:  Nancy M Petry; Sheila M Alessi; Todd A Olmstead; Carla J Rash; Kristyn Zajac
Journal:  Psychol Addict Behav       Date:  2017-06-22

4.  Drug Use Mediates the Relationship Between Depressive Symptoms and Adherence to ART Among Recently Incarcerated People Living with HIV.

Authors:  Lauren M Hill; Carol E Golin; Nisha C Gottfredson; Brian W Pence; Bethany DiPrete; Jessica Carda-Auten; Jennifer S Groves; Sonia Napravnik; David Wohl; Kevin Knight; Patrick M Flynn
Journal:  AIDS Behav       Date:  2019-08

Review 5.  New developments in behavioral treatments for substance use disorders.

Authors:  Brian D Kiluk; Kathleen M Carroll
Journal:  Curr Psychiatry Rep       Date:  2013-12       Impact factor: 5.285

6.  Prize-based contingency management for the treatment of substance abusers: a meta-analysis.

Authors:  Lois A Benishek; Karen L Dugosh; Kim C Kirby; Jason Matejkowski; Nicolle T Clements; Brittany L Seymour; David S Festinger
Journal:  Addiction       Date:  2014-05-23       Impact factor: 6.526

7.  An initial randomized controlled trial of behavioral activation for treatment of concurrent crystal methamphetamine dependence and sexual risk for HIV acquisition among men who have sex with men.

Authors:  Matthew J Mimiaga; David W Pantalone; Katie B Biello; Jackie M White Hughto; John Frank; Conall O'Cleirigh; Sari L Reisner; Arjee Restar; Kenneth H Mayer; Steven A Safren
Journal:  AIDS Care       Date:  2019-03-19

8.  Predictors of stimulant abuse treatment outcomes in severely mentally ill outpatients.

Authors:  Frank N Angelo; Michael G McDonell; Michael R Lewin; Debra Srebnik; Jessica Lowe; John Roll; Richard Ries
Journal:  Drug Alcohol Depend       Date:  2012-12-27       Impact factor: 4.492

9.  Contingency management is effective in promoting abstinence and retention in treatment among crack cocaine users in Brazil: A randomized controlled trial.

Authors:  André Q C Miguel; Clarice S Madruga; Hugo Cogo-Moreira; Rodolfo Yamauchi; Viviane Simões; Claudio J da Silva; Sterling McPherson; John M Roll; Ronaldo R Laranjeira
Journal:  Psychol Addict Behav       Date:  2016-07-21

10.  Preliminary findings: Contingency management targeting psycho-stimulant use results in secondary decreases in smoking for severely mentally ill adults.

Authors:  Michael McDonell; Sterling McPherson; Roger Vilardaga; Debra Srebnik; Frank N Angelo; Emily Leickly; Andrew J Saxon; John Roll; Richard Ries
Journal:  Am J Addict       Date:  2013-09-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.